Patent intelligence · US
US 9616015
Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
Patent details — US 9616015
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 11, 2017
- Expiration
- Apr 6, 2037
- Applicant
- DiaMedica Inc.
- Claims
- 10
- CPC classes
- A61K, A61K38/4853, A61K9/0019, A61P
Quick answer
US 9616015 (Formulations of human tissue kallikrein-1 for parenteral delivery and related methods) is held by DiaMedica Inc.. Status: granted. Granted Apr 11, 2017. Expires Apr 6, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- DiaMedica Inc.
- Grant date
- Expiration
- Claims
- 10
- CPC classes
- A61K, A61K38/4853, A61K9/0019, A61P, A61P3/10
More from DiaMedica Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12329805
Dosage forms of tissue kallikrein 1
granted -
US 11857608
Dosage forms of tissue kallikrein 1
granted -
US 11725043
Ulinastatin polypeptides
granted -
US 9839678
Human tissue kallikrein 1 glycosylation isoforms
granted -
US 9364521
Human tissue kallikrein 1 glycosylation isoforms
granted -
US 8673964
Use of drug combinations for treating insulin resistance
granted -
US 8501695
Tissue kallikrein for the treatment of diseases associated with amyloid protein
granted
Frequently asked questions
What is US patent 9616015?
US 9616015 (Formulations of human tissue kallikrein-1 for parenteral delivery and related methods) is held by DiaMedica Inc.. Status: granted. Granted Apr 11, 2017. Expires Apr 6, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9616015?
DiaMedica Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 9 pharmaceutical patents for this assignee.
When does US 9616015 expire?
Our index shows an expiration date of Apr 6, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.